Trial Profile
A Phase 2A, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Efficacy of TRC150094 in Increasing Insulin Sensitivity in Male Patients With Increased Cardiometabolic Risk
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Omzotirome (Primary)
- Indications Lipid metabolism disorders; Metabolic syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Torrent Pharmaceuticals
- 25 Sep 2013 Primary endpoint (Efficacy in increasing insulin sensitivity of TRC150094 once daily dosing for 4 weeks in male patients with increased cardiometabolic risk), has not been met, according to results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 25 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 11 Mar 2013 New source identified and integrated (Clinical Trials Registry - India: CTRI2013-03-003470).